Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Olaparib + Trabectedin|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Olaparib||Lynparza||AZD2281|KU-0059436||PARP Inhibitor (Pan) 22||Lynparza (olaparib) binds to and inhibits PARP, resulting in inhibition of DNA repair and lethality in homologous-recombination deficient cells, and may be a sensitizing agent for chemotherapy and radiotherapy (PMID: 25028150, PMID: 24225019). Lynparza (olaparib) is FDA approved for treatment of ERBB2 (HER2)-negative breast cancer with deleterious or suspected deleterious germline BRCA mutations, ovarian cancer with deleterious or suspected deleterious germline BRCA mutations and received 3 or more prior therapies, metastatic pancreatic adenocarcinoma with deleterious or suspected deleterious germline BRCA mutations as a maintenance therapy, metastatic castration-resistant prostate cancer with deleterious or suspected deleterious germline or somatic homologous recombination repair gene mutations who progressed following enzalutamide or abiraterone, as a maintenance therapy in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer and in epithelial ovarian, fallopian tube or primary peritoneal cancer with deleterious or suspected deleterious germline or somatic BRCA mutation, and in combination with Avastin (bevacizumab) as maintenance therapy in HDR defective epithelial ovarian, fallopian tube or primary peritoneal cancer as defined by deleterious or suspected deleterious BRCA mutation, and/or genomic instability (FDA.gov).|
|Trabectedin||Yondelis||ET-743||Chemotherapy - Alkylating 15||Yondelis (trabectedin) is a marine-derived alkaloid that binds to DNA and induces DNA strand breaks, leading to cell cycle arrest and cell death in tumor cells (PMID: 24755886). Yondelis (trabectedin) is FDA approved for metastatic liposarcoma or leiomyosarcoma who received prior anthracycline treatment (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||sarcoma||not applicable||Olaparib + Trabectedin||Phase Ib/II||Actionable||In a Phase Ib trial, 14% (7/50) of patients with either bone or soft tissue sarcoma demonstrated a partial response according to RECIST criteria when treated with the combination therapy of Lynparza (olaparib) and Yondelis (trabectedin) (PMID: 30217671).||30217671|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04076579||Phase II||Olaparib + Trabectedin||Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma||Recruiting||USA||0|